PNC27
Also known as PNC-27, p53-HDM2 Disruptor Peptide, Anti-Cancer Peptide PNC-27
A peptide containing p53 binding domain (residues 12-26) fused to membrane-penetrating peptide. Selectively targets cancer cells expressing HDM-2 on plasma membranes.
Regulatory Pathway
Dosing Protocol
Typical Dose
No human dose established - research compound only
Frequency
Research protocols only
Duration
Research protocols only
Timing & Administration
Administer via IV injection in animal studies - not for human use. Frequency: Research protocols only.
Popular Uses
Mechanism of Action
Contains p53 binding domain fused to membrane-penetrating peptide. Selectively targets cancer cells expressing HDM-2 on plasma membranes, induces alpha-helical conformation, creates transmembrane pores, and triggers necrotic cell death. Works independently of intracellular p53 status.
Research Summary
Evidence level: animal studies. Clinical status: Preclinical - Extensive in vitro studies, ex vivo human cancer tissue studies.
Side Effects & Safety
Important Warnings
- NOT for human use
- Temperature-dependent (optimal at 37°C)
- Unknown systemic effects.
References
No references available.
Related Peptides
Browse all →A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.
View profileA naturally occurring thymic peptide that enhances immune function.
View profileA tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.
View profile